Completed PHASE2 INTERVENTIONAL 3-arm NCT00573768

Efficacy and Safety of Diclofenac Diethylamine 2.32% Gel in Patients With Acute Ankle Sprain

A Randomized, Double-blind, Multi-center, Vehicle-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Diclofenac Diethylamine 2.32% Gel Applied Once or Twice Daily in Patients With Acute Ankle Sprain

Sponsor: Novartis

Conditions Ankle Sprain

Interventions Diclofenac diethylamine 2.32% gel Diclofenac diethylamine 2.32% gel / Placebo Placebo

Updated 6 times since 2017 Last updated: Apr 18, 2012 Started: Nov 30, 2007 Primary completion: Dec 31, 2007 Completion: Jul 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Ankle Sprain and is currently completed. Novartis leads this study, which shows 6 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Nov 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bad Bramstedt, Germany , Bad Nauheim, Germany , Bad Zwischenahn, Germany , Berlin, Germany , Bochum, Germany , Dortmund, Germany , Dresden, Germany , Düsseldorf, Germany , Eichstätt, Germany , Hamburg, Germany and 11 more locations